Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

February 28, 2011

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Cavorsi Robert

2. Date of Event Requiring Statement (Month/Day/Year)
04/19/2024

3. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ORGO]

(Last)

(First)

(Middle)

C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Vice President, Strategy

5. If Amendment, Date Original Filed (Month/Day/Year)

(Street)

CANTON, MA 02021

6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	23,579 ⁽²⁾	D
Class A Common Stock ⁽¹⁾	739 ⁽³⁾	D
Class A Common Stock ⁽¹⁾	215 ⁽³⁾	D
Class A Common Stock ⁽¹⁾	2,163 ⁽⁴⁾	D
Class A Common Stock ⁽¹⁾	4,203 ⁽⁵⁾	D
Class A Common Stock ⁽¹⁾	51,750 ⁽⁶⁾	D
Class A Common Stock ⁽¹⁾	57,434 ⁽⁷⁾	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽⁸⁾	03/09/2031	Class A Common Stock	6,519	$ 15.63	D
Stock Option (Right to Buy)	⁽⁹⁾	07/16/2031	Class A Common Stock	32,559	$ 14.45	D
Stock Option (Right to Buy)	⁽¹⁰⁾	03/01/2032	Class A Common Stock	19,935	$ 8.03	D
Stock Option (Right to Buy)	⁽¹¹⁾	03/15/2033	Class A Common Stock	81,000	$ 2.51	D
Stock Option (Right to Buy)	⁽¹²⁾	02/21/2034	Class A Common Stock	103,842	$ 3.43	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Cavorsi Robert C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON, MA 02021			Vice President, Strategy

Signatures

/s/ William R. Kolb, Attorney-in-Fact		04/29/2024
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.
(2)	Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.
(3)	The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025.
(4)	The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025.
(5)	The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026.
(6)	The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027.
(7)	The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028.
(8)	The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025.
(9)	The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025.
(10)	The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026.
(11)	The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027.
(12)	The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028.
Remarks: Exhibit 24 Power of Attorney filed herewith.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.